Site Editors
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Posted: Wednesday, February 9, 2022
Arch Oncology recently announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to AO-176, its next-generation anti-CD47 antibody, in the treatment of relapsed or refractory multiple myeloma. According to the manufacturer, this agent can lower binding to normal cells and negligible binding to red blood cells, enhance binding to CD47 in acidic tumor environments, and induce programmed and immunogenic cell death.
This novel antibody is currently in phase I/II clinical trials for the treatment of resistant myeloma (ClinicalTrials.gov identifier NCT04445701) as well as select solid tumors (NCT03834948) as monotherapy and in combinations with the standard of care.
